Yarrow (YARW) Director Ashiya Mona Receives 15,435-Share Award

What Happened Ashiya Mona, a director of Yarrow Bioscience, was granted an award that represents the right to purchase 15,435 shares of Yarrow common stock. The Form 4 reports an acquisition of 15,435 derivative shares at an exercise/price of $0.00 (reported value $0). This is a grant/award (not an open-market purchase or sale) and does not represent immediate ownership of common shares.

Key Details

• Transaction date: July 27, 2026; Form 4 filed July 29, 2026 (timely filing).
• Instrument: Derivative award/option for 15,435 shares, reported at $0.00 per share.
• Vesting (footnote): Vests in full on the earlier of (i) July 27, 2027 or (ii) the date of the next annual meeting of stockholders, subject to continued service.
• Transfer obligation (footnote): The reporting person must transfer any securities or economic benefit from these awards to OrbiMed Advisors LLC, which will provide them to OrbiMed Private Investments X, LP.
• Shares owned after transaction: Not specified in the filing.
• Transaction code: A (award/grant); not an immediate purchase or sale.

Context This filing documents a compensatory derivative award that vests in the future and is subject to service and a transfer arrangement to an institutional investor (OrbiMed Private Investments X, LP). Because it is a grant of a purchase right (derivative) rather than an immediate acquisition of common shares or a sale, it does not itself indicate an immediate change in share ownership or a market transaction.